Alector Inc. (ALEC)

Name: Alector Inc. (ALEC) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Alector Inc. (ALEC)

Stock Card

$2.34

$-0.05 (-2.09%)

As on 28-Aug-2026 16:00EDT

Market cap

$264 Mln

Revenue (TTM)

$14 Mln

P/E Ratio

P/B Ratio

19.6

Div. Yield

0 %

Alector (ALEC) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 2.32 High: 2.44

52 Week Range

Low: 1.09 High: 3.40

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-3.9 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-8.4
Debt to Equity

0
Book Value

$--
EPS

$-1.1
Face value

--
Shares outstanding

111,656,919

8 Years Aggregate

CFO

$-75.28 Mln

EBITDA

$-701.24 Mln

Net Profit

$-674.33 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Alector (ALEC)	50.0	55.0	5.9	-2.5	-26.5	-38.8	--
BSE Sensex	-8.8	0.6	1.8	-4.4	6.0	6.6	10.8
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 28-Aug-2026 | #As on 26-Oct-2023

Company	2025	2024	2023	2022	2021	2020
Alector (ALEC)	-17.5	-76.0	-13.5	-55.3	36.5	-12.2
S&P Small-Cap 600	4.0	7.0	13.9	-17.4	25.3	9.6
BSE Sensex	9.1	8.1	18.7	4.4	22.0	15.8

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
Alector (ALEC)	2.3	263.5	13.9	-117.9	-848.0	--	--	19.6
Arrowhead Pharmaceuticals (ARWR)	84.9	12,304.7	669.5	-320.0	-0.8	-71.1	--	26.4
Ascendis Pharma A/S - ADR	247.9	16,614.0	1,054.4	755.9	5.7	--	19.4	10.1
Cytokinetics Inc (CYTK)	72.1	10,682.6	71.0	-894.0	-1,175.8	--	--	60.3
Exelixis (EXEL)	54.5	13,400.0	2,435.9	860.6	31.0	43	17	7.3
Halozyme Therapeutics (HALO)	105.4	12,277.1	1,663.7	413.6	36.3	430	31.2	83.9
Krystal Biotech (KRYS)	351.5	10,258.4	440.5	241.5	33.4	18.7	42.2	7.3
Madrigal Pharmaceuticals (MDGL)	533.8	11,938.8	1,283.9	-325.1	-19.0	-57.7	--	22.9
Medpace Holdings (MEDP)	600.7	17,326.2	2,782.3	491.5	21.1	110.1	36.5	39.4
Praxis Precision MedicinesÂ Inc (PRAX)	344.8	10,496.2	0.0	-339.1	--	-30.6	--	7.6

Shareholding Pattern

View Details

About Alector (ALEC)

Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for... treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations. The company also develops its preclinical and research pipeline comprising AL064, a tau siRNA for Alzheimer's disease and other tauopathies; ADP062-ABC, an alpha-synuclein siRNA for Parkinson's disease; and ADP065-ABC, an NLRP3 siRNA for neurodegenerative conditions. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including Latozinemab and Nivisnebart. The company was founded in 2013 and is headquartered in South San Francisco, California. Read more

Co-Founder, CEO & Director

Dr. Arnon Rosenthal Ph.D.
Co-Founder, CEO & Director

Dr. Arnon Rosenthal Ph.D.
Headquarters

South San Francisco, CA
Website

https://www.alector.com

FAQs for Alector (ALEC)

What is the current share price of Alector Inc (ALEC) Today?

The share price of Alector Inc (ALEC) is $2.34 (NASDAQ) as of 28-Aug-2026 16:00 EDT. Alector Inc (ALEC) has given a return of -26.53% in the last 3 years.

What is the current PB & PE ratio of Alector Inc (ALEC)?

Since, TTM earnings of Alector Inc (ALEC) is negative, P/E ratio is not available.
The P/B ratio of Alector Inc (ALEC) is 19.57 times as on 21-Aug-2026, a 266 premium to its peers’ median range of 5.35 times.

PE & PB ratio at the end of financial year.